Study S000121

Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder - OBOE-Mayo

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07213466
Acronym: OBOE-Mayo
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: RECRUITING
Enrollment: 100
Start: 2026-01-19
Primary completion: 2028-02-01
Lead sponsor: Mayo Clinic
Conditions: Bipolar I Disorder; Bipolar II Disorder; Schizo Affective Disorder; Obesity; Weight Loss; GLP - 1
Interventions: BEHAVIORAL:Group Therapy Program; DRUG:semaglutide; DRUG:Phentermine-Topiramate; DRUG:naltrexone and bupropion (combination)
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Describe the distribution of obesity phenotypes (hungry brain, hungry gut, emotional hunger and slow burn) in patients with BD and obesity, with the goal of identifying predominant phenotype patterns within this clinical population. [From enrollment through the end of the 20-week intervention.]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.